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Abstract: Background and Methods: Anthroposophic treatment for migraine is provided by physicians and includes spe-
cial artistic and physical therapies and special medications. We conducted a prospective cohort study of 45 consecutive 
adult outpatients (89% women) starting anthroposophic treatment for migraine under routine conditions. Main outcomes 
were Average Migraine Severity (physician and patient ratings 0-10, primary outcome), Symptom Score (patient rating, 0-
10), and quality of life (SF-36); main follow-up time point was after six months.  
Results: The anthroposophic treatment modalities used were medications (67% of patients), eurythmy therapy (38%), art 
therapy (18%), and rhythmical massage therapy (13%). Median therapy duration was 105 days. In months 0-6, conven-
tional prophylactic antimigraine medications were used by 14% (n=5/36) of evaluable patients. 
From baseline to six-month follow-up, physician-rated Average Migraine Severity improved by 3.14 points (95% confi-
dence interval 2.40-3.87, p<0.001); patient-rated Average Migraine Severity improved by 2.82 points (2.05-3.64, 
p<0.001); and Symptom Score improved by 2.32 points (1.68-2.95, p<0.001). In addition, three SF-36 scales (Social 
Functioning, Bodily Pain, Vitality), the SF-36 Physical Component summary measure, and the SF-36 Health Change item 
improved significantly. All improvements were maintained at last follow-up after 24 months. Patients not using conven-
tional prophylactic antimigraine medications had improvements similar to the whole cohort. 
Conclusions: Patients with migraine under anthroposophic treatment had long-term improvement of symptoms and quality 
of life. Although the pre-post design of the present study does not allow for conclusions about comparative effectiveness, 
study findings suggest that anthroposophic therapies may be useful in the long-term care of patients with migraine. 
Keywords: Anthroposophy, combined modality therapy, drug therapy, eurythmy therapy, migraine, prospective studies. 
INTRODUCTION 
  Migraine affects 14% of adults in Europe every year [1] 
and is associated with substantial disability, reduced quality 
of life, reduced work capacity, psychiatric and somatic co-
morbidity, and increased healthcare use [2-4]. The World 
Health Organization has ranked severe migraine attacks 
among the most disabling medical conditions, along with 
psychosis, dementia, and quadriplegia [5]. Up to three-
fourths of patients with acute migraine attacks do not be-
come pain free from 5-HT1 agonists ("triptanes") [6, 7] and 
half of patients will not respond to prophylactic medications 
[6]. Many migraine patients use complementary therapies [8-
10], sometimes provided by their physicians. 
  Anthroposophic medicine (AM) is a physician-provided 
complementary therapy system founded by Rudolf Steiner 
and Ita Wegman in the 1920s [11]. AM extends the concep-
tion of human physiology beyond cellular and molecular 
mechanisms to holistic interactions of over-riding functional  
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systems (downward causality [12]). In particular, a complex 
equilibrium exists between two polar systems: the 'nerve-
sense system' (low metabolic rate, mediator of conscious-
ness) and the 'metabolic system' of the abdominal organs 
(high metabolic rate, minimal consciousness). This equilib-
rium can be distorted in human disease. In migraine, a pre-
dominance of the metabolic system (with symptoms such as 
nausea, vomiting, diarrhea, abdominal cramps) leads to dis-
turbances in the nerve-sense system (e. g. headache, sensory 
hypersensitivity, visual disturbances) [13-15]. This imbal-
ance is sought to be regulated by special AM therapies (eu-
rythmy movement exercises, art therapy, rhythmical massage 
therapy) [16] and special AM medications [14, 15, 17, 18]. 
  Eurythmy therapy is an artistic exercise therapy involv-
ing cognitive, emotional and volitional elements. In eu-
rythmy therapy sessions the patients exercise specific 
movements with the hands, the feet or the whole body. Eu-
rythmy movements are related to the sounds of vowels and 
consonants, to music intervals or to soul gestures, e. g. sym-
pathy-antipathy. Between therapy sessions the patients exer-
cise eurythmy movements daily. In AM art therapy the pa-
tients engage in painting, drawing, clay modelling, music or 
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oped from Swedish massage; special techniques include lift-
ing movements, rhythmically undulating gliding movements, 
and complex movement patterns like lemniscates [19]. 
  AM medications are prepared from plants, minerals, 
animals and from chemically defined substances and can be 
prepared in concentrated or potentised form. Potentization 
implies a successive dilution, each dilution step involving a 
rhythmic succussion (repeated shaking of liquids) or tritura-
tion (grinding of solids into lactose monohydrate). For ex-
ample, a D6 potency (also called 6X) has been potentized in 
a 1:10 dilution six times, resulting in a 1:10
-6 dilution [20]. 
Since potencies beyond D23 do not contain any molecules of 
the original substance, effects cannot readily be explained by 
molecular mechanisms. However, a systematic review of in-
vitro studies found biological effects of potencies D23 in 
nearly three-fourths of the studies and in more than two-
thirds of the studies with highest quality [21]. All AM medi-
cations are manufactured according to Good Manufacturing 
Practice and national drug regulations; quality standards of 
raw materials and manufacturing methods are described in 
the Anthroposophic Pharmaceutical Codex [20]. The avail-
able evidence suggests that AM medications and therapies 
are generally well tolerated with infrequent adverse reactions 
of mostly mild to moderate severity [19, 22]. 
  AM therapy is practised by physicians (counselling, AM 
medication) and non-medical therapists (eurythmy, art, 
rhythmical massage) in 67 countries worldwide [23]. AM 
therapy providers are certified following structured training 
programs according to international, standardized curricula. 
Therapy guidelines exist for AM medical therapy [24], eu-
rythmy therapy [25], and AM art therapy [26]. AM is prac-
tised in general practice and in specialist fields, including 
neurology, and is also integrated into intensive care and 
emergency medicine provided in hospitals, including univer-
sity teaching hospitals [19]. For patients with migraine, the 
physician will choose among the available AM therapy mo-
dalities in order to tailor the treatment to individual needs of 
the patient. AM treatments can be administered alone or 
combined with conventional antimigraine medications [14]. 
  Several studies have evaluated acute or prophylactic 
therapy for migraine with Ferrum-Quartz [19], a mixture of 
ferrous sulphate, honey and quartz, available as 150 mg cap-
sules and 10 mg tablets ('Kephalodoron' or 'Biodoron' tab-
lets) [20]. Here we present a pre-planned subgroup analysis 
of migraine patients from a study of a broader range of AM 
therapy options (eurythmy therapy, art therapy, rhythmical 
massage therapy, medications) [27]. 
  For complementary therapy systems in widespread use, 
regardless of whether evidence from randomized trials ex-
ists, it has been argued that the conventional drug research 
strategy – starting with studies of biological mechanisms and 
moving through Phase I, II and III clinical trials – is not op-
timal [28]. Another, more appropriate strategy has been pro-
posed, moving from descriptive studies (‘Phase 1’) towards 
comparative studies of the whole system and its parts, and 
ending with studies of biological mechanisms (‘Phase 5’) 
[28]. In the context of this reversed strategy, the present 
analysis addressed topics in the Phases 1-2 (therapy para-
digms, therapy use, clinical outcomes, perceived benefit, 
safety). 
MATERIALS AND METHODOLOGY 
Study Design and Objective 
  This is a prospective two-year cohort study in a real-
world medical setting. The study was initiated by the health 
insurance company Innungskrankenkasse Hamburg  as part 
of a research project on the effectiveness, costs, and safety of 
AM therapies in outpatients with chronic disease (Anthro-
posophic Medicine Outcomes Study, AMOS) [27, 29, 30]. 
The present pre-planned analysis concerned the subgroup of 
adult patients with migraine. Since this was the first prospec-
tive study of comprehensive AM treatment for this indica-
tion, the primary objective was to describe AM therapy for 
migraine (characteristics of AM therapy users, spectrum of 
AM therapy modalities used, extent of combination with 
conventional anti-migraine therapy) as well as clinical out-
comes after AM treatment under routine conditions. Further 
research questions addressed the use of health services, ad-
verse reactions, and therapy satisfaction. 
Setting, Participants, and Therapy 
  All physicians certified by the Physicians’ Association 
for Anthroposophical Medicine in Germany and working in 
an office-based practice or outpatient clinic were invited to 
participate in the AMOS study. Certification as an AM phy-
sician required a completed medical degree and a three-year 
structured postgraduate training. The participating physicians 
recruited consecutive patients starting AM therapy under 
routine clinical conditions. Patients enrolled from 1 January 
1999 to 31 December 2005 were included in the analysis if 
they fulfilled the eligibility criteria. Inclusion criteria were: 
1.  Age 17-75 years. 
2.  A diagnosis of migraine according to the criteria of 
the International Headache Society [31], assessed by 
the Kieler Kopfschmerzfragebogen, a standardized 
headache questionnaire in the German language 
[32;33], documented by the patients (for patients en-
rolled before April 2001: physician’s diagnosis, as-
sisted by a brief written clinical description). In ac-
cordance with the clinical practice guidelines of the 
Drug Commission of the German Medical Associa-
tion [34], neuroimaging was not required for routine 
diagnostics of all patients. 
3.  Starting AM therapy for migraine:  
•  AM-related consultation of at least 30 minutes fol-
lowed by new prescription of AM medication,  
•  or new referral to AM therapy (art, eurythmy or 
rhythmical massage). 
  Patients were excluded if they had previously received 
the AM therapy in question (see inclusion criteria 3) for mi-
graine. Patients were treated according to the physician’s 
discretion. AM therapy was evaluated as a whole system 
[35]. Additional costs for AM treatments were 0.1-5.2 Euro 
per daily dose of an AM medication (51 different price 
groups, median 0.2 Euro, mean 0.8 Euro); 20-32 Euro per 
AM therapy session; and 46 Euro and 92 Euro for AM con-
sultations with physicians of 30 min and 60 min duration, 
respectively. These costs were reimbursed by some but not 
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Clinical Outcomes 
  Primary outcomes were physician- and patient-rated Av-
erage Migraine Severity, documented on numerical rating 
scales [36] from 0 (“not present”) to 10 (“worst possible”), at 
six-month follow-up. 
  Secondary clinical outcomes were Symptom Score and 
quality of life. Symptom Score, the severity of one to six 
most relevant symptoms present at baseline, was assessed by 
patients on numerical rating scales from 0 (“not present”) to 
10 (“worst possible”). Quality of life was assessed with the 
SF-36 Health Survey [37] (Physical and Mental Component 
summary measures, eight scales, Health Change item). 
  Physician-rated Average Migraine Severity was docu-
mented after 0 and 6 months, while all other clinical out-
comes were documented after 0, 3, 6, 12, 18, and 24 months. 
Other Outcomes 
  Therapy outcome rating (0-10), satisfaction with therapy 
(0-10) and therapy effectiveness rating (“very effective, “ef-
fective”, “less effective”, “ineffective” or “not evaluable”) 
were documented by the patients after 6 and 12 months. 
  Adverse reactions to medications or therapies were 
documented by the patients after 6, 12, 18 and 24 months 
and by the physicians after 6 months. The documentation 
included cause, intensity (mild / moderate / severe = no / 
some / complete impairment of normal daily activities), and 
therapy withdrawal due to adverse reactions. Serious adverse 
events were documented by the physicians throughout the 
study. 
Data Collection 
  All data were documented with questionnaires returned 
in sealed envelopes to the study office. The physicians 
documented eligibility criteria; the therapists documented 
AM therapy administration; all other items were documented 
by the patients, unless otherwise stated. The patient re-
sponses were not made available to the physicians. The phy-
sicians were compensated 40 Euro (after March 2001: 60 
Euro) per included and fully documented patient, while the 
patients received no compensation. 
  The data were entered twice by two different persons into 
Microsoft
® Access 97 (Microsoft Corp., Redmond, WA, 
USA). The two datasets were compared and discrepancies 
resolved by checking with the original data. Non-AM medi-
cations were coded according to the Anatomical Therapeutic 
Chemical Classification Index. 
Quality Assurance, Adherence to Regulations 
  The study was approved by the Ethics Committee of the 
Faculty of Medicine Charité, Humboldt University, Berlin, 
Germany, and was conducted according to the Declaration of 
Helsinki and largely following the ICH Guideline for Good 
Clinical Practice E6. Written informed consent was obtained 
from all patients before enrolment. 
Data Analysis 
  The data analysis was performed for all patients fulfilling 
the eligibility criteria, using SPSS
® 14.0.1 (SPSS Inc., Chi-
cago, Ill, USA) and StatXact
® 5.0.3 (Cytel Software Corpo-
ration, Cambridge, MA, USA). T-test was used for continu-
ous data with normal distribution; Wilcoxon Signed-Rank 
test was used for paired continuous data with non-normal 
distribution; McNemar test and Fisher’s exact test were used 
for dichotomous data. All tests were two-tailed. Significance 
criterion was p < 0.05. Since this was a descriptive study, no 
adjustment for multiple comparisons was performed [38]. 
Pre-post effect sizes were calculated as Standardized Re-
sponse Mean (= mean change score divided by the standard 
deviation of the change score) and classified as minimal (< 
0.20), small (0.20-0.49), medium (0.50-0.79), and large ( 
0.80) [39, 40]. Clinical outcomes were analyzed with re-
placement of missing values by the last value carried for-
ward. 
  Two pre-planned sensitivity analyses (SA1-SA2) were 
performed to assess the influence of natural recovery and 
adjunctive therapy on the 0-6-month outcome of physician- 
and patient-rated Average Migraine Severity. SA1 concerned 
natural recovery, which was assumed to be unlikely in pa-
tients with disease duration of at least one year [41]. The 
sample was therefore restricted to patients with disease dura-
tion of at least 12 months prior to study enrolment. SA2 con-
cerned the effects of prophylactic antimigraine medications: 
The sample was restricted to patients not using prophylactic 
antimigraine medications during the first six study months. 
RESULTS  
Participating Physicians and Therapists 
  The patients were enrolled by 30 physicians with four 
different qualifications (27 general practitioners, one neu-
rologist, one internist, and one gynaecologist). Comparing 
these physicians to AM-certified physicians in Germany 
with the same four qualifications but without study patients 
(n = 225), no significant differences were found regarding 
gender (60.0% vs. 58.5% males), number of years in practice 
(16.1 ± 6.9 vs. 19.3 ± 8.9), and the proportion of physicians 
working in primary care (90.0% vs. 92.0%). Mean age was 
44.9 ± 5.9 and 48.3 ± 8.0 years in physicians with and with-
out study patients, respectively (mean difference 3.4 years, 
95% confidence interval 0.4-6.3 years, p = 0.027). 
  The patients were treated by 31 different AM therapists 
(art, eurythmy, rhythmical massage). Comparing these 
therapists to certified therapists without study patients (n = 
1137), no significant differences were found regarding gen-
der (87.1% vs. 80.7% women), age (mean 48.2 ± 9.3 vs. 50.3 
± 9.4 years) or the number of years since therapist qualifica-
tion (10.5 ± 6.9 vs. 13.2 ± 8.7 years). 
Patient Recruitment and Follow-Up 
  A total of 79 patients starting AM therapies for headache 
were screened for inclusion. Of these patients, 45 fulfilled all 
eligibility criteria and were included in the analysis. 34 pa-
tients were not included; in 27 of these patients the eligibility 
criteria were not fulfilled (the indication for AM therapy was 
not migraine but another headache disorder). The remaining 
seven patients were potentially eligible but not included for 
the following reasons: patients’ baseline questionnaire miss-
ing (n = 3), physician’s baseline documentation missing (n = 
3), patients’ and physicians’ baseline questionnaire dated > 
30 days apart (n = 1). 
  A total of 89% (40/45) of patients were enrolled by gen-
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The physicians’ settings were primary care practices (89% of 
evaluable patients, n = 39/44), referral practice (7%, n = 3), 
and outpatient clinics (5%, n = 2). 
  The last patient follow-up ensued on 9 May 2007. A total 
of 96% (n = 43/45) of patients returned at least one follow-
up questionnaire. The patients were administered a total of 
225 follow-up questionnaires, out of which 157 (70%) were 
returned. Follow-up rates were 89% (n = 40/45), 76%, 69%, 
60%,  and 56%  after 3, 6, 12, 18,  and 24 months, respec-
tively. Respondents (n = 34) and non-respondents (n = 11) of 
the six-month follow-up questionnaire did not differ signifi-
cantly  regarding  age,  gender,  disease  duration  or  baseline 
parameters (physician- and patient-rated Average  Migraine 
Severity, Symptom Score). Corresponding dropout analysis 
for the 24-month follow-up also showed no significant dif-
ferences between respondents (n = 25) and non-respondents 
(n = 20). The physician six-month follow-up documentation 
was available for 82% (n = 37/45) of patients. 
Baseline Characteristics 
  The patients were recruited from 12 of 16 German fed-
eral states.  Mean age was 39.5 ± 11.1 years (range 17-61 
years, Table 1). A total of 89% (n = 40/45) of the patients 
were women. Median duration of the migraine disorder was 
12.0  years  (interquartile  range  [IQR]  2.5-20.0,  range  4 
months to 40 years, mean 13.6 ± 10.1 years). The number of 
days with headache  in the past month was documented in 
patients enrolled after March 2001 (n = 23) and was 1 day in 
4% (n = 1/23), 2-6 days in 61% (n = 14), 7-10 days in 26% 
(n = 6), 11-15 days in 0% (n = 0), and > 15 days in 9% (n = 
2), with a median number of 5.0 days (mean 6.8 ± 6.3 days). 
  A current comorbid disease was present in 78% (35/45) 
of patients. Most common comorbid diseases, classified by 
the  International  Statistical  Classification  of  Diseases  and 
Related  Health  Problems,  10th  Revision,  were  F00-F99 
Mental and Behavioural Disorders (24%, n = 17 of 70 diag-
noses),  N00-N99  Diseases  of  the  Genito-urinary  System 
(17%), L00-L99 Diseases of the Skin and Subcutaneous Tis-
sue (13%), and  M00-M99  Musculoskeletal Diseases (9%). 
Further baseline data are presented in Table 1. 
Therapy 
AM Therapies 
  At study enrolment, the duration of the consultation with 
the AM physician was < 30 min in 40% (n = 18/45) of pa-
tients, 30-44 min in 40%, 45-59 min in 9%, and   60 min in 
11%. At enrolment 22% (n = 10/45) of patients fulfilled In-
Table 1.  Baseline Data of Study Population 
 
Study patients  German population  Item  Subgroup 
N  %  % 
Source 
17-29 years  7/45  16%   
30-39 years  20/45  44%   
40-49 years  9/45  20%   
Age 
50-61 years  9/45  20%   
 
Low (level 1)  3/45  7%  43% 
Intermediate (level 2)  23/45  51%  43% 
Education [42] 
High (level 3)  19/45  42%  14% 
[43] 
Wage earners  Economically active patients  1/35  3%  18%  [44] 
Unemployed during last 12 months  Economically active patients  1/35  3%  10%  [44] 
Living alone  7/45  16%  21%  [44] 
Net family income < 900   per month  4/33  12%  16%  [44] 
Male  0/5  0%  28%  Alcohol use daily (patients) vs. almost daily (Germany) 
Female  1/40  3%  11% 
[45] 
Male  0/5  0%  37%  Regular smoking 
Female  2/40  5%  28% 
[46] 
Sports activity   1 hour weekly  Age 25-69  17/41  41%  39%  [47] 
Male  4/5  80%  56%  Body mass index   25 (overweight) 
Female  8/40  20%  39% 
[44] 
Permanent work disability pension  1/45  2%  3%  [48] 
Severe disability status  2/45  4%  12%  [49] 
Sick leave days in the last 12 months (mean ±SD)  Economically active patients  19.0 ±36.7  17.0  [50] 
CES-D   24 points = depressive range   19/43  44%  17%  [51] 
4-11 months  3/45  7% 
1-4 years  10/45  22% 
Duration of migraine disorder 
  5 years  32/45  71% 
   
CES-D: Center for Epidemiological Studies Depression Scale, German version. 104     The Open Neurology Journal, 2010, Volume 4  Hamre et al. 
clusion Criterion 3a (AM-related consultation of  30 min-
utes followed by new prescription of AM medication), 38% 
(n = 17) fulfilled Inclusion Criterion 3b (referral to AM art, 
eurythmy or rhythmical massage therapy), and 40% (n = 18) 
fulfilled Inclusion Criteria 3a and 3b. Of the 35 patients re-
ferred to AM art/eurythmy/massage therapy, 89% (n = 31) 
had the planned AM therapy, 3% (n = 1) did not have AM 
therapy, and for 9% (n = 3) the AM therapy documentation 
is incomplete. AM therapies used were eurythmy therapy (n 
= 17 patients), rhythmical massage therapy (n = 6), and art 
therapy (n = 8). The AM eurythmy/art/massage therapy 
started median 9 (IQR 0-35) days after enrolment. Median 
therapy duration was 105 days (IQR 77-246 days), median 
number of therapy sessions was 12 (IQR 10-20). AM medi-
cations were used by 67% (n = 30/45) of patients. The most 
frequently used AM medications in months 0-6 were Fer-
rum-Quartz (n = 14 patients, thereof n = 7 using 150 mg cap-
sules and n = 7 using 10 mg tablets), and Phosphorous dilu-
tion (n = 3 patients – contains potentised yellow phosphorus; 
used by the three patients in a D5, D6, and D20 potency, 
respectively).  
Use of Conventional Antimigraine Medications in Months 
0-6 
  Medications to treat acute migraine attacks were used by 
53% (n = 19/36) of evaluable patients; medication groups 
used were non-opioid analgesics (44%), non-steroid anti-
inflammatory agents (6%), and 5-HT1 agonists (14%). The 
total number of days with use of medication to treat acute 
migraine attacks in months 0-6 was 1-9 days (n = 9 patients), 
10-19 days (n = 3), and 20-90 days (n = 19). Prophylactic 
antimigraine medications were used by 14% (n = 5/36); 
medications used were antidepressants (8%), cyclandelate 
(3%), and flunarazine (3%). The total number of days of use 
of prophylactic medications was 5 days (n = 1), 60-180 days 
(n = 3), and unknown (n = 1).  
Clinical Outcomes 
  All clinical outcomes were improved from baseline at all 
subsequent follow-ups (exception: the SF-36 scale Role 
Emotional in months 0-6) (Table 2, Figs. 1-3). For seven of 
the 14 outcomes (physician- and patient-rated Average Mi-
graine Severity, Symptom Score, the SF-36 scales Social 
Functioning, Bodily Pain, and Vitality and the SF-36 Health 
Change item) all improvements from baseline were signifi-
cant at all follow-ups. Three further outcomes (SF-36 Physi-
cal and Mental Component summary measures, SF-36 scale 
Mental Health) were significantly improved at three or four 
out of five follow-ups. 
  At six-month follow-up, an improvement of  50% of 
baseline Average Migraine Severity was observed in 52% (n 
=23/44) of evaluable patients for physician rating and 45% 
(n = 20/44) for patient rating. Effect sizes for the 0-6-month 
comparison were large for three outcomes (physician- and 
patient-rated Average Migraine Severity, Symptom Score), 
medium for three outcomes (SF-36 Social Function, Bodily 
Pain, Health Change), small for six outcomes, and minimal 
for two outcomes (Table 2).  
  We performed two sensitivity analyses of the 0-6-month 
outcome of physician- and patient-rated Average Migraine 
Severity (Table 3: SA1-SA2; see Methods for further de-
scription). For physician rating, the individual analyses re-
sulted in a reduction of the average 0-6 month improvement 
Table 2.  Clinical Outcomes 0-6 Months 
 
0 months  6 months  0-6 month difference*  Outcome (range)  N 
Mean (SD)  Mean (SD)  Mean (95%-CI)  P-value 
SRM 
Average Migraine Severity, Physician 
(0-10) 
44  7.20 (1.37)  4.07 (2.48)  3.14 (2.40-3.87)  <0.001  1.30 
Average Migraine Severity, Patient (0-
10) 
44  6.77 (1.79)  3.93 (2.44)  2.84 (2.05-3.64)  <0.001  1.09 
Symptom Score (0-10)  45  6.40 (1.43)  4.08 (1.90)  2.32 (1.68-2.95)  <0.001  1.10 
SF-36 Physical Component  44  42.70 (8.64)  46.14 (8.04)  3.44 (1.16 to 5.73)  0.004  0.46 
SF-36 Mental Component  44  39.51 (12.55)  41.55 (11.76)  2.03 (-1.07 to 514)  0.194  0.20 
SF-36 Scales (0-100)             
Physical Function  45  82.89 (21.91)  84.28 (20.29)  1.39 (-3,25 to 6.02)  0.549  0.09 
Role Physical  45  45.56 (39.27)  56.11 (38.86)  10.56 (-0.94 to 22.05)  0.071  0.28 
Role Emotional  45  61.48 (43.78)  57.78 (43.46)  -3.70 (-16.73 to 9.32)  0.570  0.09 
Social Functioning  45  54.44 (22.16)  67.78 (24.20)  13.33 (6.47 to 20.19)  <0.001  0.58 
Mental Health  45  55.69 (20.00)  59.47 (18.28)  3.78 (-0.80 to 8.35)  0.103  0.25 
Bodily Pain  45  41.07 (19.45)  55.89 (24.13)  14.82 (8.12 to 21.53)  <0.001  0.66 
Vitality  45  40.44 (18.27)  47.44 (18.51)  7.00 (2.08 to 11.92  0.006 0.43 
General Health  44  54.95 (20.14)  59.09 (18.17)  4.14 (-0.70 to 8.98)  0.092  0.26 
SF-36 Health Change**  45  3.16 (1.02)  2.40 (1.18)  0.76 (0.31 to 1.21)  0.001  0.51 
*Positive differences indicate improvement. **SF-36 Health Change: range from 1 (“much better now than one year ago”) to 5 (“much worse now than one year ago”). SRM: Stan-
dardized Response Mean effect size (minimal: < 0.20, small: 0.20-0.49, medium: 0.50-0.79, large: 0.80). Anthroposophic Therapy for Migraine  The Open Neurology Journal, 2010, Volume 4    105 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Average Migraine Severity. 
Range: 0 “not present”, 10 “worst possible”. Physician and patient ratings. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Symptom Score. 
Range: 0 “not present”, 10 “worst possible”. 
of maximum 6% (3.142.95 points). Combining both 
analyses, the improvement was reduced by 10% (3.142.82 
points). For patient rating, the individual analyses resulted in 
a reduction of the improvement of maximum 8% 
(2.942.61 points). Combining both analyses, the im-
provement was reduced by 2% (2.842.78 points). 
Other Outcomes 
  At six-month follow-up, the patients’ average therapy 
outcome rating (numeric scale from 0 “no help at all” to 10 
“helped very well”) was 7.33 ±2.42 and patient satisfaction 
with therapy (from 0 “very dissatisfied” to 10 “very satis-
fied”) was 7.72 ±2.05. The patients’ effectiveness rating of 
eurythmy, art or rhythmical massage therapy was positive 
(“very effective” or “effective”) in 76% (n = 19/25) of 
evaluable patients who had started therapy, and negative 
(“less effective”, “ineffective” or “not evaluable”) in 24%. 
The ratings of therapy outcome, satisfaction and effective-
ness did not change significantly between 6- and 12-month 
follow-up. 
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Fig. (3). SF-36 Scales, SF-36 Health Change Item. 
SF-36 scales: Range 0-100, higher scores indicate better health. SF-36 Health Change: Range from 1 (“much better now than one year ago”) 
to 5 (“much worse now than one year ago”). 
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Table 3.  Average Migraine Severity 0-6 Months: Sensitivity Analyses (SA) 
 
0 months  6 months  0-6 month difference  Outcome / Analysis  N 
Mean (SD)  Mean (SD)  Mean (95%-CI)  P-value 
Physician rating           
Main analysis: Patients with evaluable data at baseline  44  7.20 (1.37)  4.07 (2.48)  3.14 (2.40-3.87)  < 0.001 
SA1: Patients with a disease duration of  12 months   41  7.17 (1.41)  4.22 (2.50)  2.95 (2.20-3.70)  < 0.001 
SA2: Patients not using prophylactic antimigraine medications 
in months 0-6 
30  7.33 (1.27)  4.23 (2.45)  3.10 (2.23-3.97)  < 0.001 
SA1 + SA2   27  7.30 (1.32)  4.48 (2.44)  2.82 (1.93-3.70)  < 0.001 
Patient rating          
Main analysis: Patients with evaluable data at baseline  44  6.77 (1.79)  3.93 (2.44)  2.84 (2.05-3.64)  < 0.001 
SA1: Patients with a disease duration of  12 months   41  6.71 (1.83)  4.10 (2.43)  2.61 (1.81-3.41)  < 0.001 
SA2: Patients not using prophylactic antimigraine medications 
in months 0-6 
30  6.63 (1.52)  3.53 (2.43)  3.10 (2.12-4.08)  < 0.001 
SA1 + SA2  27  6.52 (1.55)  3.74 (2.44)  2.78 (1.77-3.79)  < 0.001 
 
  The frequency of reported adverse drug reactions was 3% 
(n = 1 of 30 users) for AM medications and 9% (n = 3 of 34 
users) for non-AM medications (p = 0.616). Adverse drug 
reactions of severe intensity were reported in three patients 
using non-AM medications (unspecified psychic symptoms 
from homoeopathic arsenicum album; nightmares from 
amitriptyline; skin blisters from estradiol/norethisterone tab-
lets), while medication was stopped due to reported adverse 
reactions in one patient using AM medication (skin blisters 
from rosemary ointment). No adverse reactions from non-
medication therapies occurred. No serious adverse events 
occurred. 
DISCUSSION 
  This is the first prospective evaluation of comprehensive 
AM treatment for migraine. We aimed to obtain information 
on AM therapy for this indication under routine outpatient 
conditions in Germany and studied adults starting AM ther-
apy for migraine. Two-thirds of patients used non-
medication AM therapies; two-thirds used AM medications; 
one in seven patients also used conventional prophylactic 
medications. Under AM treatment, significant and sustained 
improvements of migraine severity and quality of life were 
observed.  
  Strengths of this study include a detailed assessment of 
the therapy setting and therapy-related factors, a long follow-
up period, and high representativeness: 11% of all AM-
certified physicians seeing migraine patients in Germany 
participated; the participating AM physicians and therapists 
resembled all eligible physicians and therapists with respect 
to socio-demographic characteristics; and 87% of screened 
and eligible patients were enrolled. These features suggest 
that the study mirrors contemporary AM practice to a high 
degree.  
  To assess the routine clinical practice, where the selec-
tion of AM therapy options will vary according to individual 
needs, we analyzed AM as a whole system [35]. The sample 
size of AM therapy modality subgroups (eurythmy, art, 
rhythmical massage, medical) did not allow for subgroup 
analysis. The influence of the AM therapy modality and 
other therapy variables (e. g. duration of the consultation 
with the physician at study enrolment, number of AM ther-
apy sessions) on clinical outcomes has been assessed in a 
multivariate analysis of adult AMOS patients with migraine 
and other chronic indications [52]. 
  Another limitation in regard to sample size applies to the 
number of days with headache. This outcome, widely used in 
migraine studies, was only documented in a subset of pa-
tients, the documentation did not distinguish between mi-
graine and interval headaches,  and the number of patients 
with evaluable data at six-month follow-up (n = 13) did not 
allow for outcome analysis. 
  Since the study had a long recruitment period, the study 
physicians were not able to participate throughout the period 
and to screen and enrol all eligible patients (criteria: see 
Methods section). For a different subset of patients from the 
AMOS project (patients referred to AM therapies for any 
chronic indication and enrolled before 1 April 2001), it was 
estimated that physicians enrolled every fourth eligible pa-
tient [53]. This selection could bias results if physicians were 
able to predict therapy response and if they preferentially 
screened and enrolled such patients for whom they expected 
a particularly favorable outcome. In this case one would ex-
pect the degree of selection (= the proportion of eligible vs. 
enrolled patients) to correlate positively with clinical out-
comes. That was not the case, the correlation was almost 
zero (Spearman-Rho -0.04, p = 0.496, n = 364 [53]). Like-
wise, another analysis of 500 adult patients enrolled into 
AMOS in the period 1999-2005 showed no correlation be-
tween the degree of selection and the 0-6 month difference 
of Symptom Score [52]. These analyses do not suggest that 
the participating physicians' expectations of future therapy 
response led to any selection bias affecting clinical out-
comes.  
  A limitation of the study is the absence of a comparison 
group receiving conventional treatment or no therapy. Ac-
cordingly, one must consider several other causes for the 
observed improvements apart from the AM treatment. We 
therefore conducted a sensitivity analysis of physician- and 108     The Open Neurology Journal, 2010, Volume 4  Hamre et al. 
patient-rated Average Migraine Severity, estimating the in-
fluence of natural recovery and adjunctive treatment with 
prophylactic antimigraine medications. These two factors 
together explained up to 10% of the 0-6 month improvement. 
Dropout rates increased from 11% after three months to 44% 
after 24 months. Dropouts and respondents had comparable 
baseline data, and in a telephone survey of non-respondents 
from a different subset of the AMOS sample, the proportion 
of patients with clinical deterioration at 24-month follow-up 
was comparable in dropouts and respondents [54]. In the 
outcome analyses, attrition bias was minimised by replacing 
missing values of clinical outcomes by the last value carried 
forward. Non-medication therapies such as acupuncture [55] 
or biofeedback [56] were not documented in the study and 
could therefore not be evaluated. According to a previous 
analysis from this research program [41], regression to the 
mean due to symptom fluctuation with preferential self-
selection to therapy and study inclusion at symptom peaks 
explained up to 0.43 points (11%) of the improvement of an 
outcome corresponding to physician-rated Average Migraine 
Severity in this analysis. Other possible confounders are 
psychological factors and non-specific effects. However, 
since AM therapy was evaluated as a whole system [35], the 
question of specific therapy effects vs. non-specific effects 
(placebo effects, context effects, physician-patient interac-
tions, patient expectations etc.) was not an issue of the pre-
sent analysis. 
  Because 14 clinical outcomes were analysed (Table 2), 
the issue of multiple hypothesis testing arises [38]. However, 
eight of the 14 comparisons at six-month follow-up showed 
significant improvements and six comparisons had p-values 
 0.001 – a constellation that would not be expected to occur 
by chance. (E. g. a Bonferroni adjustment for 14 tests would 
have indicated p < 0.004 as significance level). 
  Since AM treatment was to be evaluated under routine 
conditions, therapy was administered at the discretion of the 
physicians and therapists and not according to standardized 
protocols. This raises the question of whether study interven-
tions would be replicable in future studies. However, AM 
therapy providers worldwide are trained according to highly 
standardized curricula, specifying e. g. individual eurythmy 
movements for specific diseases, constitution types, and 
movement patterns. Therefore, relevant therapy differences 
across settings would not be expected. Moreover, in this 
study, any local therapy differences would probably be offset 
by the large number of participating AM physicians and 
therapists. 
  The present analysis was restricted to clinical outcomes 
and did not assess costs. In an analysis of 487 adult patients 
from the AMOS study with migraine and other chronic indi-
cations, costs of AM medications and therapies in the first 
study year amounted to 12% of all costs of healthcare and 
productivity loss [57]. These extra costs of the new AM 
treatment in AMOS were offset by a reduction of inpatient 
hospital costs [29, 57]. Other, comparative evaluations indi-
cate similar or lower costs in AM therapy settings, compared 
to conventional settings [19, 58]. 
  This study provides the first data on comprehensive AM 
treatment for migraine in AM settings. The female/male ratio 
in this predominantly primary care sample (8.0/1.0) was 
higher than among migraineurs in the population (3.0/1.0) 
[59] and also higher than in primary care studies of AM 
medications for migraine (1.6-3.1/1.0) [60, 61]. The higher 
proportion of women in this sample might possibly reflect 
that women are more likely than men to engage in creative 
therapies such as AM art and eurythmy therapy. The use of 
non-opioid analgesics (44% of patients), 5-HT1 agonists 
(14%), and prophylactic antimigraine agents (14%) was 
similar to the use among migraineurs in Germany [62, 63] or 
France [64] during the study. 
  Baseline migraine disability, assessed by the number of 
days with headache in the past month (median 5.0 days), was 
higher than in the German population with migraine (median 
2.2 days) [65], but the proportion of patients with >10 days 
with headache was similar (9% vs. 12%) [63]. Quality of life 
at baseline, assessed with the SF-36 Health Survey, was 
worse than in other migraine studies (median difference for 
all SF-36 scores in all evaluable studies: 0.42 standard devia-
tions) [66]. The proportion of responders at six-month fol-
low-up (patients with 50% improvement of Average Mi-
graine Severity from baseline: 45-52%) was of the same or-
der of magnitude as in trials of prophylactic antimigraine 
medications [6]. Notably, in prophylactic trials a response 
was defined as 50% reduction in number of migraine attacks, 
which was not documented in the present study; therefore 
this comparison is necessarily approximate. A systematic 
comparison of identical quality of life outcomes (SF-36) in 
migraine cohorts receiving other therapies showed improve-
ments of largely of the same order of magnitude as in this 
study [66]. 
  Previous studies have found beneficial effects of single 
AM medications on migraine [19]. In accordance with these 
findings, we found improvement of migraine symptoms and 
quality of life under comprehensive AM treatment. A nota-
ble finding was that three-fourths of study patients did not 
use anti-migraine medications in the first six months after 
enrolment, apart from non-opioid analgesics. Some migraine 
patients will not profit from medication; other patients stop 
taking medications due to adverse reactions or reject them, e. 
g. because they are passive. Even non-medication therapies 
for migraine are not suitable for all patients: some therapies 
are also passive (e. g. acupuncture or chiropractics) and oth-
ers may be perceived as monotonous (e. g. biofeedback). In 
this context, the AM approach, with recourse to artistic exer-
cise therapies as well as medication and rhythmical massage 
therapy, may be a welcome therapy option for some mi-
graineurs. 
CONCLUSIONS  
  In this study, adult migraine patients under AM treatment 
had long-term reduction of symptoms and improvement of 
quality of life. Improvements were similar in patients not 
using antimigraine prophylactic medications. Although the 
pre-post design of the present study does not allow for con-
clusions about comparative effectiveness, study findings 
suggest that AM therapies may be useful in the long-term 
care of patients with migraine. 
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